Top 3 Financial Stocks That May Crash This Quarter
MarketAxess, Genworth Financial and XP show overbought RSI readings, signaling potential warnings for momentum-focused investors.
News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
MarketAxess, Genworth Financial and XP show overbought RSI readings, signaling potential warnings for momentum-focused investors.
J.Jill (NYSE:JILL) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Keybanc analyst Jason Celino maintains ServiceTitan (NASDAQ:TTAN) with a Overweight and lowers the price target from $120 to $110.
Filed: 2026-09-09 AccNo: 0001193125-26-385961 Size: 160 KB Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Keybanc analyst Matthew Gillmor maintains InnovAge Holding (NASDAQ:INNV) with a Overweight and raises the price target from $13 to $14.
Filed: 2026-09-09 AccNo: 0001193125-26-385959 Size: 224 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
BMO Capital analyst Kelly Crago initiates coverage on Gap (NYSE:GAP) with a Market Perform rating and announces Price Target of $23.
Filed: 2026-09-09 AccNo: 0001628280-26-061036 Size: 911 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Baker Hughes (BKR) stock rose in premarket trading after raising its FY26 revenue guidance to $28.5B–$30.3B following the Chart acquisition.
The program provides no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC), helping address
Keybanc analyst Alex Markgraff maintains Chime Financial (NASDAQ:CHYM) with a Overweight and raises the price target from $33 to $40.
Medicare drug spending faces fresh pressure as more seniors hit the $2,000 cap, raising concerns over costs.
FCC will vote on unlocking 1,000+ MHz of spectrum, potentially boosting Starlink capacity and satellite broadband competition.
CNBC's final trades spotlighted Pinnacle Financial, Cheniere Energy and Freeport-McMoRan, with analysts citing bullish outlooks and strong results.
Citizens analyst Patrick Walravens reiterates Braze (NASDAQ:BRZE) with a Market Outperform and maintains $35 price target.
The contract establishes a framework for Trinovium and RTI to develop and deploy direct-to-chip liquid cooling solutions for artificial intelligence ("AI"), high-performance computing ("HPC") and modular
Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030The Company expects XP-8121 peak net revenue potential of $1 to $3
Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has repaid
Filed: 2026-09-09 AccNo: 0001140361-26-035986 Size: 5 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Filed: 2026-09-09 AccNo: 0001867096-26-000077 Size: 3 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company") today announced its plan to establish GridFeed™, together with its DeepSolar operations, as a standalone, wholly owned subsidiary, creating a
ENvue Medical , Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement and therapeutic technologies, today
Stephens & Co. analyst Pooran Sharma reiterates Casey's General Stores (NASDAQ:CASY) with a Overweight and maintains $975 price target.